Gastroenterology

Portfolio expansion: RIDA®UNITY E. coli Stool Panel I and III working together Current situation: Differentiating pathogenic E. coli strains is becoming increasingly important in gastrointestinal [...]

For World IBD Day we would like to draw your attention to the Inflammatory Bowel Disease (IBD). About ten million people worldwide (around three million in Europe) suffer from this chronic [...]

Highly effective and well tolerated: the anti-inflammatory medication golimumab, known under the trade name Simponi®, is a valuable treatment option for patients with rheumatic diseases as well [...]

More than five million people worldwide suffer from chronic inflammatory bowel disease (IBD) including Crohn’s disease and ulcerative colitis. World IBD Day on May 19 brings awareness to this [...]

Adalimumab (ADM) revolutionized the treatment of patients with inflammatory bowel diseases. Despite its therapeutic success, up to 40 % of patients do not respond to adalimumab induction [...]

Patients with Crohn’s disease, ulcerative colitis or other inflammatory diseases are often treated with adalimumab. However, long-term therapy success is not always achieved. As a recent study [...]

RIDA®QUICK ADM Monitoring is a rapid test for adalimumab drug concentration monitoring which supports timely dose adjustments in clinical practice. A poster about the validation of the test was [...]

Through early detection, almost all colorectal cancers can be cured or even prevented. The exam is effective and simple – and it is not performed often enough. The new invitation process is [...]

Chronic inflammatory diseases like Crohn’s disease, ulcerative colitis, and rheumatism respond well to treatment with the TNF-α blockers infliximab and adalimumab. Monitoring the [...]

The guideline of the Joint National Committee (G-BA) requires laboratories to switch to a new test procedure for early detection of colon cancer. We have summarized what you need to consider in [...]